
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of October 2019

Commission File Number: 001-36515

Materialise NV

Technologielaan 15
3001 Leuven
Belgium
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

This Form 6-K is incorporated by reference into the registrant's Registration Statement on Form F-3 (File No. 333-213649).

Third Quarter 2019 Financial Results

Except as otherwise required by the context, references to “Materialise,” “Company,” “we,” “us” and “our” are to Materialise NV and its subsidiaries.

Third Quarter 2019 Results

Total revenue for the third quarter of 2019 increased 8.0% to 50,449 kEUR compared to 46,732 kEUR for the third quarter of 2018.

Revenue from our Materialise Software segment increased 10.0% to 10,860 kEUR for the third quarter of 2019 from 9,874 kEUR for the same quarter last year.

Revenue from our Materialise Medical segment increased 20.8% to 15,488 kEUR for the third quarter of 2019 compared to 12,824 kEUR for the same period in 2018. Compared to the same quarter in 2018, revenues from medical devices and services grew 25.0%, and revenues from our medical software grew 12.7%. On August 6, 2019, we acquired a mix of existing and new shares, resulting in total shareholding of 75% in Engimplan, a Brazil-based manufacturer of orthopedic and cranio-maxillofacial (CMF) implants and instruments. All shares were fully paid for in cash. The acquisition increased the scope of our Materialise Medical segment’s operations and had a positive impact on our results of operations for the third quarter of 2019.

Revenue from our Materialise Manufacturing segment increased 0.5% to 24,127 kEUR for the third quarter of 2019 from 24,012 kEUR for the third quarter of 2018.

Gross profit was 29,023 kEUR, or 57.5% of total revenue, for the third quarter of 2019 compared to 26,418 kEUR, or 56.5% of total revenue, for the third quarter of 2018.

Research and development (“R&D”), sales and marketing (“S&M”) and general and administrative (“G&A”) expenses increased, in the aggregate, 11.2% to 27,439 kEUR for the third quarter of 2019 from 24,665 kEUR for the third quarter of 2018.

Net other operating income increased to 1,332 kEUR from 571 kEUR for the third quarter of 2018.

Operating result increased to 2,916 kEUR from 2,324 kEUR for the same period in the prior year.

Net financial result was (966) kEUR compared to 268 kEUR for the prior-year period. The share in loss of joint venture amounted to (41) kEUR compared to (47) kEUR for the same period last year.

The third quarter of 2019 contained income tax expenses of (908) kEUR, compared to (230) kEUR in the third quarter of 2018.

As a result of the above, net profit for the third quarter of 2019 was 1,001 kEUR, compared to 2,316 kEUR for the same period in 2018. Total comprehensive income for the third quarter of 2019, which includes exchange differences on translation of foreign operations, was 1,067 kEUR compared to 2,329 kEUR for the same period in 2018.

Adjusted EBITDA increased to 8,022 kEUR from 7,034 kEUR. The Adjusted EBITDA margin (Adjusted EBITDA divided by total revenue) for the third quarter of 2019 was 15.9% compared to 15.1% in the third quarter of 2018.

Segment EBITDA from our Materialise Software segment increased to 3,769 kEUR from 3,384 kEUR while the segment EBITDA margin (the segment’s EBITDA divided by the segment’s revenue) was 34.7% compared to 34.3% in the prior-year period.

Segment EBITDA from our Materialise Medical segment was 2,795 kEUR compared to 2,475 kEUR while the segment EBITDA margin decreased from 19.3% to 18.0% for the third quarter of 2019.

Segment EBITDA from our Materialise Manufacturing segment increased to 3,862 kEUR from 3,405 kEUR while the segment EBITDA margin increased to 16.0% from 14.2% for the third quarter of 2018.

At September 30, 2019, we had cash and equivalents of 131,095 kEUR compared to 115,506 kEUR at December 31, 2018. Gross debt amounted to 131,618 kEUR (including 5,201 kEUR of lease liabilities recognized under the new accounting standard IFRS 16, and our drawing in July 2019 of the second tranche of 25,000 kEUR from our 35,000 kEUR credit facility with the European Investment Bank), as compared to 106,038 kEUR at December 31, 2018. Cash flow from operating activities for the third quarter of 2019 amounted to a new quarterly record of 13,897 kEUR compared to 7,234 kEUR for the same period in 2018, as a result of the combination of high

EBITDA and working capital improvements of 6,636 kEUR. Total capital expenditures for the quarter amounted to 5,628 kEUR. This amount included 301 kEUR of capitalized R&D expenditures from medical programs.

Shareholders' equity at September 30, 2019 was 139,894 kEUR compared to 135,989 kEUR at December 31, 2018.

Note on Comparability

As a result of the implementation of the new accounting standard IFRS 16, we have recognized additional lease assets and liabilities in the amount of 4,998 kEUR at January 1, 2019. At the end of the third quarter of 2019, the total commitment of lease assets and liabilities amounted to 5,238 kEUR. Our Adjusted EBITDA for the third quarter of 2019 was affected positively by the new standard as a result of the rental payments decrease of 632 kEUR; however, our operating profit was impacted by (20) kEUR as depreciation expenses increased by 652 kEUR.

Non-IFRS Measures

Materialise uses EBITDA and Adjusted EBITDA as supplemental financial measures of its financial performance. EBITDA is calculated as net profit plus income taxes, financial expenses (less financial income), shares of loss in a joint venture and depreciation and amortization. Adjusted EBITDA is determined by adding non-cash stock-based compensation expenses and acquisition-related expenses of business combinations to EBITDA. Management believes these non-IFRS measures to be important measures as they exclude the effects of items which primarily reflect the impact of long-term investment and financing decisions, rather than the performance of the Company's day-to-day operations. As compared to net profit, these measures are limited in that they do not reflect the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in the Company's business, or the charges associated with impairments. Management evaluates such items through other financial measures such as capital expenditures and cash flow provided by operating activities. The Company believes that these measurements are useful to measure a company's ability to grow or as a valuation measurement. The Company's calculation of EBITDA and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. EBITDA and Adjusted EBITDA should not be considered as alternatives to net profit or any other performance measure derived in accordance with IFRS. The Company's presentation of EBITDA and Adjusted EBITDA should not be construed to imply that its future results will be unaffected by unusual or non-recurring items.

Exchange Rate

This document contains translations of certain euro amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from euros to U.S. dollars in this document were made at a rate of EUR 1.00 to USD 1.0889, the reference rate of the European Central Bank on September 30, 2019.

About Materialise

Materialise incorporates nearly 30 years of 3D printing experience into a range of software solutions and 3D printing services, which form the backbone of the 3D printing industry. Materialise's open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines one of the largest groups of software developers in the industry with one of the largest 3D printing facilities in the world.

Cautionary Statement on Forward-Looking Statements

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations, plans, objectives, strategies and prospects, both financial and business. When used in this report, the words "estimate," "expect," "anticipate," "project," "plan," "intend," "believe," "forecast," "will," "may," "could," "might," "aim," "should," and variations of such words or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this report. These expectations, beliefs and projections are expressed in good faith and the Company believes there is a reasonable basis for them. However, the Company cannot offer any assurance that our expectations, beliefs and projections will actually be achieved. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. All of the forward-looking statements are subject to risks and uncertainties that may cause the Company's actual results to differ materially

from our expectations, including risk factors described in the Company's annual report on Form 20-F filed with the U.S. Securities and Exchange Commission. There are a number of risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements contained in this report.

The Company is providing this information as of the date of this report and does not undertake any obligation to update any forward-looking statements contained in this report as a result of new information, future events or otherwise, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.

Consolidated income statements (Unaudited)

In 000	For the three months ended September 30,			For the nine months ended September 30,	
	2019	2019	2018	2019	2018
	U.S.\$	€	€	€	€
Revenue	54,934	50,449	46,732	145,968	135,707
Cost of sales	(23,331)	(21,426)	(20,314)	(64,838)	(60,546)
Gross profit	31,603	29,023	26,418	81,129	75,161
Gross profit as % of revenue	57.5%	57.5%	56.5%	55.6%	55.4%
Research and development expenses	(6,126)	(5,626)	(5,634)	(17,411)	(17,080)
Sales and marketing expenses	(14,749)	(13,545)	(11,292)	(38,797)	(33,733)
General and administrative expenses	(9,004)	(8,269)	(7,739)	(24,453)	(22,926)
Net other operating income (expenses)	1,450	1,332	571	3,959	2,961
Operating (loss) profit	3,175	2,916	2,324	4,427	4,383
Financial expenses	(1,239)	(1,138)	(1,039)	(2,647)	(3,556)
Financial income	187	172	1,308	900	2,739
Share in loss of joint venture	(44)	(41)	(47)	(245)	(291)
(Loss) profit before taxes	2,079	1,909	2,546	2,434	3,275
Income taxes	(989)	(908)	(230)	(2,037)	(773)
Net (loss) profit for the period	1,089	1,001	2,316	397	2,502
Net (loss) profit attributable to:					
The owners of the parent	1,011	929	2,316	325	2,502
Non-controlling interest	78	72	–	72	–
Earnings per share attributable to owners of the parent					
Basic	0.02	0.02	0.04	0.01	0.05
Diluted	0.02	0.02	0.04	0.01	0.05
Weighted average basic shares outstanding	52,891	52,891	51,507	52,891	48,770
Weighted average diluted shares outstanding	52,970	52,970	52,319	52,930	49,532

Consolidated statements of comprehensive income (Unaudited)

In 000	For the three months ended			For the nine	
	September 30,			months ended	
	2019	2019	2018	2019	2018
	U.S.\$	€	€	€	€
Net profit (loss) for the period	1,089	1,001	2,316	397	2,502
Other comprehensive income					
Exchange difference on translation of foreign operations	73	67	13	225	(29)
Other comprehensive income (loss), net of taxes	73	67	13	225	(29)
Total comprehensive income (loss) for the year, net of taxes	1,162	1,067	2,329	623	2,473
Total comprehensive income (loss) attributable to:					
The owners of the parent	1,173	1,077	2,329	623	2,473
Non-controlling interest	(11)	(10)	–	–	–

Consolidated statement of financial position (Unaudited)

	As of September 30, 2019	As of December 31, 2018
	€	€
In 000		
Assets		
Non-current assets		
Goodwill	23,301	17,491
Intangible assets	25,181	26,326
Property, plant & equipment	99,108	92,537
Investments in joint ventures		
Deferred tax assets	489	315
Other non-current assets	10,408	7,237
Total non-current assets	158,488	143,906
Current assets		
Inventories	11,916	9,986
Trade receivables	36,983	36,891
Other current assets	8,573	6,936
Cash and cash equivalents	131,095	115,506
Total current assets	188,566	169,319
Total assets	347,054	313,225

In 000	As of September 30, 2019 €	As of December 31, 2018 €
Equity and liabilities		
Equity		
Share capital	3,050	3,050
Share premium	136,944	136,637
Consolidated reserves	(1,517)	(1,848)
Other comprehensive income	(1,542)	(1,850)
Equity attributable to the owners of the parent	136,935	135,989
Non-controlling interest	2,959	–
Total equity	139,894	135,989
Non-current liabilities		
Loans & borrowings	116,026	92,440
Deferred tax liabilities	6,234	6,226
Deferred income	4,932	4,587
Other non-current liabilities	1,666	868
Total non-current liabilities	128,859	104,121
Current liabilities		
Loans & borrowings	15,592	13,598
Trade payables	18,291	18,667
Tax payables	2,907	2,313
Deferred income	24,473	23,195
Other current liabilities	17,040	15,342
Total current liabilities	78,301	73,115
Total equity and liabilities	347,054	313,225

Consolidated statement of cash flows (Unaudited)

in 000	For the nine months ended	
	September 30,	
	2019	2018
	€	€
Operating activities		
Net (loss) profit for the period	398	2,502
<i>Non-cash and operational adjustments</i>		
Depreciation of property, plant & equipment	10,722	8,632
Amortization of intangible assets	3,360	3,902
Share-based payment expense	258	557
Loss (gain) on disposal of property, plant & equipment	141	(148)
Movement in provisions	66	13
Movement reserve for bad debt	(135)	255
Financial income	(900)	(224)
Financial expense	2,647	1,474
Impact of foreign currencies	(432)	(433)
Share in loss of a joint venture (equity method)	245	291
(Deferred) income taxes	2,012	773
Other	4	164
Working capital adjustment & income tax paid		
Increase in trade receivables and other receivables	3,593	(3,174)
Decrease (increase) in inventories	8	584
Increase in trade payables and other payables	2,263	5,230
Income tax paid & interest received	(1,514)	(2,133)
Net cash flow from operating activities	22,737	18,265

in 000

	For the nine months ended September 30,	
	2019	2018
	€	€
Investing activities		
Purchase of property, plant & equipment	(10,325)	(14,923)
Purchase of intangible assets	(1,588)	(1,181)
Proceeds from the sale of property, plant & equipment & intangible assets (net)	(3)	1,264
Available for sale investments		(50)
Advances on capital increases	(875)	
Convertible loan to third party	(2,500)	–
Investments in subsidiary, net of cash acquired	(7,765)	–
Interest received	–	126
Net cash flow used in investing activities	(23,066)	(14,764)
Financing activities		
Proceeds from loans & borrowings	29,000	31,043
Repayment of loans & borrowings	(8,608)	(16,257)
Repayment of finance leases	(2,288)	(2,350)
Capital increase	–	60,110
Direct attributable expense of capital increase	–	(4,103)
Interest paid	(1,713)	(1,142)
Other financial income (expense)	(451)	(182)
Net cash flow from (used in) financing activities	15,941	67,119
Net increase of cash & cash equivalents	15,611	70,620
Cash & cash equivalents at beginning of the year	115,506	43,175
Exchange rate differences on cash & cash equivalents	162	827
Cash & cash equivalents at end of the period	131,279	114,622

Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited)

In 000	For the three months ended September 30,		For the nine months ended September 30,	
	2019	2018	2019	2018
	€	€	€	€
Net profit (loss) for the period	1,001	2,316	397	2,503
Income taxes	908	230	2,037	773
Financial expenses	1,138	1,039	2,647	3,556
Financial income	(172)	(1,308)	(900)	(2,739)
Share in loss of joint venture	41	47	245	291
Depreciation and amortization	4,904	4,519	14,082	12,534
EBITDA	7,820	6,843	18,512	16,917
Non-cash stock-based compensation expense (1)	60	191	256	557
Acquisition-related expenses of business combinations (2)	140	–	140	–
ADJUSTED EBITDA	8,022	7,034	18,908	17,474

- (1) Non-cash stock-based compensation expenses represent the cost of equity-settled and cash-settled share-based payments to employees.
- (2) Acquisition-related expenses of business combinations represent expenses incurred in connection with the Engimplan acquisition.

Segment P&L (Unaudited)

In 000	<u>Materialise Software</u> €	<u>Materialise Medical</u> €	<u>Materialise Manu- facturing</u> €	<u>Total segments</u> €	<u>Unallocated (1)(2)</u> €	<u>Consoli- dated</u> €
For the three months ended September 30, 2019						
Revenues	10,860	15,488	24,127	50,474	(26)	50,449
Segment EBITDA	3,769	2,795	3,862	10,426	(2,404)	8,022
Segment EBITDA %	34.7%	18.0%	16.0%	20.7%		15.9%

For the three months ended September 30, 2018						
Revenues	9,874	12,824	24,012	46,710	22	46,732
Segment EBITDA	3,384	2,475	3,405	9,264	(2,230)	7,034
Segment EBITDA %	34.3%	19.3%	14.2%	19.8%		15.1%

In 000	<u>Materialise Software</u> €	<u>Materialise Medical</u> €	<u>Materialise Manu- facturing</u> €	<u>Total segments</u> €	<u>Unallocated (1)(2)</u> €	<u>Consoli- dated</u> €
For the nine months ended September 30, 2019						
Revenues	29,529	43,600	72,861	145,990	(22)	145,968
Segment EBITDA	8,785	7,306	10,393	26,484	(7,576)	18,908
Segment EBITDA %	29.8%	16.8%	14.3%	18.1%		13.0%

For the nine months ended September 30, 2018						
Revenues	27,331	37,170	71,031	135,532	175	135,707
Segment EBITDA	8,568	6,659	8,802	24,028	(6,554)	17,474
Segment EBITDA %	31.3%	17.9%	12.4%	17.7%		12.9%

- (1) Unallocated Revenues consist of occasional one-off sales in our core competencies not allocated to any of our segments.
- (2) Unallocated segment EBITDA consists of corporate research and development, corporate headquarter costs and other operating income (expense), and the added non-cash stock-based compensation expenses and acquisition related expenses of business combinations that are included in Adjusted EBITDA.

Reconciliation of Net Profit (Loss) to Segment EBITDA (Unaudited)

In 000	For the three months ended September 30,		For the nine months ended September 30,	
	2019	2018	2019	2018
	€	€	€	€
Net profit (loss) for the period	1,001	2,316	397	2,502
Income taxes	908	230	2,037	773
Financial cost	1,138	1,043	2,647	3,556
Financial income	(172)	(1,308)	(900)	(2,739)
Share in loss of joint venture	41	47	245	291
Operating profit	2,916	2,324	4,427	4,383
Depreciation and amortization	4,904	4,519	14,082	12,534
Corporate research and development	497	483	1,510	1,469
Corporate headquarter costs	2,978	2,437	8,753	7,514
Other operating income (expense)	(726)	(499)	(1,833)	(1,872)
Segment EBITDA	10,426	9,264	26,484	24,028

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MATERIALISE NV

By: /s/ Wilfried Vancraen

Name: Wilfried Vancraen

Title: Chief Executive Officer

Date: October 31, 2019